Yangli Pharmaceutical Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $14M

  • Investors
  • 8

Yangli Pharmaceutical General Information

Description

Developer of therapeutic drug candidates designed to address unmet medical needs in oncology and infectious diseases. The company offers small-molecule drug discovery, pharmaceutical formulation research, preclinical development capabilities, and translational research expertise, enabling biotechnology companies and healthcare organizations to advance novel therapies through the drug development process.

Contact Information

Website
yanglics.zhulu76.com
Formerly Known As
Shenzhen Yangli Pharmaceutical Technology, Shenzhen Mait Pharmaceutical Technology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1107, Building 1, Haozhang Building, Dongxin Street
  • Gongshu District
  • Hangzhou, Zhejiang 900000
  • China
+86 0371
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 1107, Building 1, Haozhang Building, Dongxin Street
  • Gongshu District
  • Hangzhou, Zhejiang 900000
  • China
+86 0371

Yangli Pharmaceutical Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yangli Pharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 13-Nov-2025 $14M Completed Generating Revenue
5. Later Stage VC (Series C) 08-Apr-2025 Completed Generating Revenue
4. Secondary Transaction - Private 18-Nov-2024 Completed Generating Revenue
3. Later Stage VC 27-Jun-2023 Completed Generating Revenue
2. Early Stage VC 08-Jul-2022 Completed Generating Revenue
1. Early Stage VC 01-Feb-2021 Completed Generating Revenue
To view Yangli Pharmaceutical’s complete valuation and funding history, request access »

Yangli Pharmaceutical Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Yangli Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024131945-A1 Parp1 inhibitors Inactive 23-Dec-2022

Yangli Pharmaceutical Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Qiming Venture Partners Venture Capital Minority
Suzhou Equity Investment Fund Management Fund of Funds Minority
Hangzhou Tailong Venture Capital Partnership Growth/Expansion Minority
Taikun Fund Venture Capital Minority
Jiangsu Winfast Investment Asset Manager Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Yangli Pharmaceutical FAQs

  • When was Yangli Pharmaceutical founded?

    Yangli Pharmaceutical was founded in 2018.

  • Where is Yangli Pharmaceutical headquartered?

    Yangli Pharmaceutical is headquartered in Hangzhou, China.

  • What industry is Yangli Pharmaceutical in?

    Yangli Pharmaceutical’s primary industry is Drug Delivery.

  • Is Yangli Pharmaceutical a private or public company?

    Yangli Pharmaceutical is a Private company.

  • What is Yangli Pharmaceutical’s current revenue?

    The current revenue for Yangli Pharmaceutical is .

  • How much funding has Yangli Pharmaceutical raised over time?

    Yangli Pharmaceutical has raised $14M.

  • Who are Yangli Pharmaceutical’s investors?

    Qiming Venture Partners, Suzhou Equity Investment Fund Management, Hangzhou Tailong Venture Capital Partnership, Taikun Fund, and Jiangsu Winfast Investment are 5 of 8 investors who have invested in Yangli Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process